Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

Yosef Yarden (Editor), Moshe Elkabets (Editor)

Research output: Book/ReportBookpeer-review

Abstract

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
Original languageAmerican English
Place of PublicationCham
PublisherSpringer
Number of pages242
Edition1st ed. 2018
ISBN (Electronic)9783319679327
ISBN (Print)9783319679303
DOIs
StatePublished - 2018

Publication series

NameResistance to Targeted Anti-Cancer Therapeutics
Volume15

ULI publications

  • uli
  • Cancer -- Research
  • Cancer research

Fingerprint

Dive into the research topics of 'Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways'. Together they form a unique fingerprint.

Cite this